首页> 外文期刊>BMC Public Health >Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study
【24h】

Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study

机译:近二十年来印度黑热病后皮肤利什曼病(PKDL)病例的临床流行病学分析:一项基于医院的回顾性研究

获取原文
           

摘要

Patients with Post kala-azar dermal leishmaniasis (PKDL) are considered a reservoir of Leishmania donovani. It is imperative to identify and treat them early for control of visceral leishmaniasis (VL), a current priority in the Indian subcontinent. We explored trends in clinico-epidemiological features of PKDL cases over last two decades, for improving management of the disease. Clinically suspected cases were diagnosed with rK39 strip test followed by parasitological confirmation by microscopy and/or PCR/qPCR in skin tissue/slit aspirates. Patients were treated with antimonials till 2008 and subsequently with miltefosine. The study indicated higher incidence of PKDL cases in areas of high endemicity for VL, with 20?% cases reporting no history of VL. Approximately 26?% cases of PKDL were initially misdiagnosed at primary health centers. Duration between onset of PKDL and diagnosis was above 12?months in 80?% cases. Diagnostic sensitivity was 32-36?% with microscopy and 96–100?% with PCR/qPCR. Compliance to treatment was over 85?% with miltefosine while 15?% with antimonials. Relapse rate with miltefosine was up to 13.2?%. PKDL patients tend to delay reporting and are often misdiagnosed. Confirmatory diagnosis using minimally invasive skin slit aspirate samples would help overcome such issues. There was a paradigm shift in compliance with miltefosine; however, increasing relapse rate indicated the need for newer therapies with oral formulations.
机译:患黑热病后皮肤利什曼病(PKDL)的患者被认为是利什曼原虫的储存库。必须尽早发现并治疗它们,以控制内脏利什曼病(VL),这是印度次大陆目前的优先重点。我们探索了过去二十年中PKDL病例临床流行病学特征的趋势,以改善疾病的管理。临床疑似病例被诊断为rK39试纸条,然后通过显微镜和/或PCR / qPCR在皮肤组织/狭缝抽吸物中进行了寄生虫学确认。直到2008年,患者均接受了抗生素治疗,随后接受了米替福辛治疗。研究表明,在VL的高度流行地区,PKDL病例的发生率较高,其中20%的病例没有VL的病史。最初在初级卫生中心误诊了约26%的PKDL病例。在PKDL发作到诊断之间的持续时间在80%的病例中超过12周。显微镜的诊断敏感性为32-36%,PCR / qPCR为96-100%。 Miltefosine对治疗的依从性超过85%,而锑剂则为15%。米替福辛的复发率高达13.2%。 PKDL患者往往会延迟报告,并经常被误诊。使用微创皮肤狭缝抽吸样品进行确诊可以帮助克服此类问题。遵从米替福新发生了范式转变;然而,增加的复发率表明需要采用口服制剂的新疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号